Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix 2/15/2026 Earnings Report

Nanobiotix logo
$41.01 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$41.02 +0.01 (+0.02%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanobiotix EPS Results

Actual EPS
-$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
$3.42 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
Date
2/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanobiotix Earnings Headlines

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives $26.67 Consensus Price Target from Brokerages
May 24 at 5:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30797906
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 23 at 8:34 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nanobiotix-announces-full-exercise-of-underwriters-over-allotment-option-bringing-gross-proceeds-of-offering-to-approximately-100-million-1036189444
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel
 |  Behind the Markets (Ad)
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300358/0/en/nanobiotix-announces-full-exercise-of-underwriters-over-allotment-option-bringing-gross-proceeds-of-offering-to-approximately-100-million.html
Nanobiotix stock slides on $87M follow-on offering
May 21, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4595609-nanobiotix-stock-slides-on-87m-follow-on-offering
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299514/0/en/nanobiotix-announces-pricing-of-oversubscribed-85m-global-offering.html
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma. The company is actively expanding its global footprint with ongoing trials in the United States, Asia, and other regions. Partnerships and collaborations with academic institutions and pharmaceutical companies support the clinical development and potential commercialization of its lead candidate. In addition to NBTXR3, Nanobiotix continues to explore next-generation nanotherapies and combination strategies aimed at enhancing standard oncology protocols.

Founded in 2003 by Dr. Laurent Levy and a team of researchers, Nanobiotix combines expertise in physics, chemistry and oncology to address unmet needs in cancer care. The company maintains R&D facilities in Europe and the United States and is led by Dr. Levy, who serves as Chief Executive Officer. Through its science-driven approach, Nanobiotix seeks to deliver safer, more effective treatment options for patients worldwide and to transform the way radiotherapy is applied in solid tumor oncology.

View Nanobiotix Profile
Earnings Tools